The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy
Author:
Affiliation:
1. Roche Innovation Center Zurich, Roche Pharma Research and Early Development (pRED), Schlieren, Switzerland
Funder
there is no funding
Publisher
Informa UK Limited
Subject
Immunology,Immunology and Allergy
Link
https://www.tandfonline.com/doi/pdf/10.1080/19420862.2023.2167189
Reference150 articles.
1. Co-Stimulatory Receptors in Cancers and Their Implications for Cancer Immunotherapy
2. cDNA sequences of two inducible T-cell genes.
3. Potential role of 4-1BB in T cell activation. Comparison with the costimulatory molecule CD28.
4. Inducible T cell antigen 4-1BB. Analysis of expression and function.
5. 4-1BB signaling beyond T cells
Cited by 34 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Photothermal therapy co-localized with CD137 agonism improves survival in an SM1 melanoma model without hepatotoxicity;Nanomedicine;2024-09-03
2. CD137 expression and signal function drive pleiotropic γδ T-cell effector functions that inhibit intracellular M. tuberculosis growth;Clinical Immunology;2024-09
3. Identification of costimulatory molecule signatures for evaluating prognostic risk in non-small cell lung cancer;Heliyon;2024-09
4. Manipulating the 4-1BB Pathway to Cure HBV;Infectious Diseases & Immunity;2024-08-02
5. Bispecific antibodies: advancing precision oncology;Trends in Cancer;2024-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3